ID: ALA1271208

Max Phase: Preclinical

Molecular Formula: C30H39N5O3S

Molecular Weight: 549.74

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(C#N)nc(C)c1C(=O)N1C[C@H]2CN(CCC(c3ccccc3)C3CCN(S(C)(=O)=O)CC3)C[C@H]2C1

Standard InChI:  InChI=1S/C30H39N5O3S/c1-21-15-27(16-31)32-22(2)29(21)30(36)34-19-25-17-33(18-26(25)20-34)12-11-28(23-7-5-4-6-8-23)24-9-13-35(14-10-24)39(3,37)38/h4-8,15,24-26,28H,9-14,17-20H2,1-3H3/t25-,26+,28?

Standard InChI Key:  RUGPFTCINDXZAE-XFAILSGYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 549.74

Molecular Weight (Monoisotopic): 549.2774

AlogP: 3.42

#Rotatable Bonds: 7

Polar Surface Area: 97.61

Molecular Species: BASE

HBA: 6

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 9.88

CX LogP: 1.95

CX LogD: -0.49

Aromatic Rings: 2

Heavy Atoms: 39

QED Weighted: 0.53

Np Likeness Score: -1.15

References

1. Wanner J, Chen L, Lemoine RC, Kondru R, Jekle A, Heilek G, deRosier A, Ji C, Berry PW, Rotstein DM..  (2010)  Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series.,  20  (22): [PMID:20855212] [10.1016/j.bmcl.2010.08.118]

Source

Source(1):

• Scientific Literature